Your browser doesn't support javascript.
loading
Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)
The Korean Journal of Internal Medicine ; : 24-27, 2007.
Article in English | WPRIM | ID: wpr-199149
ABSTRACT
Behcet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Remission Induction / Gastrointestinal Agents / Behcet Syndrome / Tumor Necrosis Factor-alpha / Treatment Outcome / Colectomy / Disease Progression / Gastrointestinal Diseases / Antibodies, Monoclonal Limits: Humans / Male Language: English Journal: The Korean Journal of Internal Medicine Year: 2007 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Remission Induction / Gastrointestinal Agents / Behcet Syndrome / Tumor Necrosis Factor-alpha / Treatment Outcome / Colectomy / Disease Progression / Gastrointestinal Diseases / Antibodies, Monoclonal Limits: Humans / Male Language: English Journal: The Korean Journal of Internal Medicine Year: 2007 Type: Article